NPM1 and acute myeloid leukemia: In contrast, kinetics for NPM1 mutated AML seem to be highly variable and dependent on the molecular context, as faster relapses were linked to the presence of a FLT3-ITD with a median time to relapse of 3.5 and 6.5 months for FLT3-ITD-positive and FLT3-ITD-negative patients, respectively [75].